Table 2.
Characteristics | UMOD | MUC1 | REN (het.) | HNF1B | DNAJB11 (het.) | SEC61A1 |
---|---|---|---|---|---|---|
Estimated prevalence/reported cases | Around 30 families described globally [11] | ∼19% in selected patient cohorts, ranging from 5% to 31% and highest in children with CAKUT [29] |
|
|
||
ESKD onset and renal survival |
|
|
Median renal survival: 75 years, 95% CI 72.5–77.5 years [12] | Unknown | ||
ESKD onset: age distribution | 18–87 years [8] | 16–>80 years [10] | 15 years to >80 years | Highly variable, ESKD can occur before age 2 years [31] | 55–89 years | Infantile onset of CKD, one patient with ESKD ∼70 years and one patient with CKD G4 at 53 years |
Extrarenal clinical features | Prevalent (∼80%) and early-onset gout (median: 27 years) [9] | Gout less prevalent (∼25%) and later onset (median: 45 years) [9] |
|
|
|
|
Laboratory features |
|
– |
|
|
– |
|
Kidney imaging features |
|
Small-to-normal size kidneys [32] | Wide spectrum of renal appearances including pre-natal hyperechogenic kidneys, cysts, renal hypo/dysplasia, horseshoe kidney |
|
small dysplastic kidneys (± cysts) [34] |
FEuric acid, fractional excretion of uric acid.